Now showing items 316-335 of 703

    • Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. 

      Litchfield, K; Levy, M; Orlando, G; Loveday, C; Law, PJ; Migliorini, G; Holroyd, A; Broderick, P; Karlsson, R; Haugen, TB; Kristiansen, W; Nsengimana, J; Fenwick, K; Assiotis, I; Kote-Jarai, Z; Dunning, AM; Muir, K; Peto, J; Eeles, R; Easton, DF; Dudakia, D; Orr, N; Pashayan, N; UK Testicular Cancer Collaboration; PRACTICAL Consortium; Bishop, DT; Reid, A; Huddart, RA; Shipley, J; Grotmol, T; Wiklund, F; Houlston, RS; Turnbull, C (2017-07)
      Genome-wide association studies (GWAS) have transformed understanding of susceptibility to testicular germ cell tumors (TGCTs), but much of the heritability remains unexplained. Here we report a new GWAS, a meta-analysis ...
    • Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. 

      Brough, R; Gulati, A; Haider, S; Kumar, R; Campbell, J; Knudsen, E; Pettitt, SJ; Ryan, CJ; Lord, CJ (2018-10)
      Although defects in the RB1 tumour suppressor are one of the more common driver alterations found in triple-negative breast cancer (TNBC), therapeutic approaches that exploit this have not been identified. By integrating ...
    • Identification of miRSNPs associated with the risk of multiple myeloma. 

      Macauda, A; Calvetti, D; Maccari, G; Hemminki, K; Försti, A; Goldschmidt, H; Weinhold, N; Houlston, R; Andersen, V; Vogel, U; Buda, G; Varkonyi, J; Sureda, A; Martinez Lopez, J; Watek, M; Butrym, A; Sarasquete, ME; Dudziński, M; Jurczyszyn, A; Druzd-Sitek, A; Kruszewski, M; Subocz, E; Petrini, M; Iskierka-Jażdżewska, E; Raźny, M; Szombath, G; Marques, H; Zawirska, D; Chraniuk, D; Halka, J; Hove Jacobsen, SE; Mazur, G; García Sanz, R; Dumontet, C; Moreno, V; Stępień, A; Beider, K; Pelosini, M; Manuel Reis, R; Krawczyk-Kulis, M; Rymko, M; Avet-Loiseau, H; Lesueur, F; Grząśko, N; Ostrovsky, O; Jamroziak, K; Vangsted, AJ; Jerez, A; Tomczak, W; Zaucha, JM; Kadar, K; Sainz, J; Nagler, A; Landi, S; Gemignani, F; Canzian, F (2017-02)
      Multiple myeloma (MM) is a malignancy of plasma cells usually infiltrating the bone marrow, associated with the production of a monoclonal immunoglobulin (M protein) which can be detected in the blood and/or urine. Multiple ...
    • Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. 

      Went, M; Sud, A; Försti, A; Halvarsson, B-M; Weinhold, N; Kimber, S; van Duin, M; Thorleifsson, G; Holroyd, A; Johnson, DC; Li, N; Orlando, G; Law, PJ; Ali, M; Chen, B; Mitchell, JS; Gudbjartsson, DF; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Campo, C; Bandapalli, OR; Einsele, H; Gregory, WA; Gullberg, U; Hillengass, J; Hoffmann, P; Jackson, GH; Jöckel, K-H; Johnsson, E; Kristinsson, SY; Mellqvist, U-H; Nahi, H; Easton, D; Pharoah, P; Dunning, A; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; Nickel, J; Nöthen, MM; Rafnar, T; Ross, FM; da Silva Filho, MI; Thomsen, H; Turesson, I; Vangsted, A; Andersen, NF; Waage, A; Walker, BA; Wihlborg, A-K; Broyl, A; Davies, FE; Thorsteinsdottir, U; Langer, C; Hansson, M; Goldschmidt, H; Kaiser, M; Sonneveld, P; Stefansson, K; Morgan, GJ; Hemminki, K; Nilsson, B; Houlston, RS; PRACTICAL consortium (2018-09-13)
      Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous ...
    • Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. 

      Went, M; Sud, A; Försti, A; Halvarsson, B-M; Weinhold, N; Kimber, S; van Duin, M; Thorleifsson, G; Holroyd, A; Johnson, DC; Li, N; Orlando, G; Law, PJ; Ali, M; Chen, B; Mitchell, JS; Gudbjartsson, DF; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Campo, C; Bandapalli, OR; Einsele, H; Gregory, WA; Gullberg, U; Hillengass, J; Hoffmann, P; Jackson, GH; Jöckel, K-H; Johnsson, E; Kristinsson, SY; Mellqvist, U-H; Nahi, H; Easton, D; Pharoah, P; Dunning, A; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; Nickel, J; Nöthen, MM; Rafnar, T; Ross, FM; da Silva Filho, MI; Thomsen, H; Turesson, I; Vangsted, A; Andersen, NF; Waage, A; Walker, BA; Wihlborg, A-K; Broyl, A; Davies, FE; Thorsteinsdottir, U; Langer, C; Hansson, M; Goldschmidt, H; Kaiser, M; Sonneveld, P; Stefansson, K; Morgan, GJ; Hemminki, K; Nilsson, B; Houlston, RS; PRACTICAL consortium (2018-09-13)
      Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous ...
    • Identification of neutral tumor evolution across cancer types. 

      Williams, MJ; Werner, B; Barnes, CP; Graham, TA; Sottoriva, A (2016-03)
      Despite extraordinary efforts to profile cancer genomes, interpreting the vast amount of genomic data in the light of cancer evolution remains challenging. Here we demonstrate that neutral tumor evolution results in a ...
    • Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. 

      Ruark, E; Seal, S; McDonald, H; Zhang, F; Elliot, A; Lau, K; Perdeaux, E; Rapley, E; Eeles, R; Peto, J; Kote-Jarai, Z; Muir, K; Nsengimana, J; Shipley, J; UK Testicular Cancer Collaboration (UKTCC); Bishop, DT; Stratton, MR; Easton, DF; Huddart, RA; Rahman, N; Turnbull, C (2013-06)
      Testicular germ cell tumor (TGCT) is the most common cancer in young men and is notable for its high familial risks. So far, six loci associated with TGCT have been reported. From genome-wide association study (GWAS) ...
    • Identification of recurrent noncoding mutations in B-cell lymphoma using capture Hi-C. 

      Cornish, AJ; Hoang, PH; Dobbins, SE; Law, PJ; Chubb, D; Orlando, G; Houlston, RS (2019-01)
      The identification of driver mutations is fundamental to understanding oncogenesis. Although genes frequently mutated in B-cell lymphoma have been identified, the search for driver mutations has largely focused on the ...
    • Identifying Genetic Dependencies in Cancer by Analyzing siRNA Screens in Tumor Cell Line Panels. 

      Campbell, J; Ryan, CJ; Lord, CJ (2018-01)
      Loss-of-function screening using RNA interference or CRISPR approaches can be used to identify genes that specific tumor cell lines depend upon for survival. By integrating the results from screens in multiple cell lines ...
    • IGF1-mediated human embryonic stem cell self-renewal recapitulates the embryonic niche. 

      Wamaitha, SE; Grybel, KJ; Alanis-Lobato, G; Gerri, C; Ogushi, S; McCarthy, A; Mahadevaiah, SK; Healy, L; Lea, RA; Molina-Arcas, M; Devito, LG; Elder, K; Snell, P; Christie, L; Downward, J; Turner, JMA; Niakan, KK (2020-02-07)
      Our understanding of the signalling pathways regulating early human development is limited, despite their fundamental biological importance. Here, we mine transcriptomics datasets to investigate signalling in the human ...
    • IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance. 

      Selfe, J; Goddard, NC; McIntyre, A; Taylor, KR; Renshaw, J; Popov, SD; Thway, K; Summersgill, B; Huddart, RA; Gilbert, DC; Shipley, JM
      Testicular germ cell tumours (TGCTs) are the most frequent malignancy and cause of death from solid tumours in the 20- to 40-year age group. Although most cases show sensitivity to cis-platinum-based chemotherapy, this is ...
    • IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance. 

      Selfe, J; Goddard, NC; McIntyre, A; Taylor, KR; Renshaw, J; Popov, SD; Thway, K; Summersgill, B; Huddart, RA; Gilbert, DC; Shipley, JM (2018-02)
      Testicular germ cell tumours (TGCTs) are the most frequent malignancy and cause of death from solid tumours in the 20- to 40-year age group. Although most cases show sensitivity to cis-platinum-based chemotherapy, this is ...
    • IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL) 

      Del Giudice, I; Davis, Z; Matutes, E; Osuji, N; Parry-Jones, N; Morilla, A; Brito-Babapulle, V; Oscier, D; Catovsky, D (2006-07)
      B-prolymphocytic leukemia (B-PLL) is a rare disease with poor prognosis. To further characterize the biological features of this disease, we analyzed immunoglobulin heavy chain (IgVH) mutations, ZAP-70 and CD38 in 19 cases ...
    • Immuno-PET in Pontine Glioma: More Than Meets the Eye? 

      Oyen, WJG; Jones, C (2018-04)
    • Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. 

      Tucker, ER; Tall, JR; Danielson, LS; Gowan, S; Jamin, Y; Robinson, SP; Banerji, U; Chesler, L (2017-08)
      Targeted inhibition of anaplastic lymphoma kinase (ALK) is a successful approach for the treatment of many ALK-aberrant malignancies; however, the presence of resistant mutations necessitates both the development of more ...
    • Immunohistochemical distinction of haematogones from B lymphoblastic leukaemia/lymphoma or B-cell acute lymphoblastic leukaemia (B-ALL) on bone marrow trephine biopsies: a study on 62 patients 

      Matutes, E (2011-08)
      Haematogones are normal, maturing B-cell precursors. They can be confused with neoplastic immature lymphoid cells of B lymphoblastic leukaemia/lymphoma or B-cell acute lymphoblastic leukaemia (B-ALL). Though multicolour ...
    • Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial. 

      Detre, SI; Ashley, S; Mohammed, K; Smith, IE; Powles, TJ; Dowsett, M (2017-03)
      The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (n = 2,471) were randomly assigned to tamoxifen ...
    • Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. 

      Newey, A; Griffiths, B; Michaux, J; Pak, HS; Stevenson, BJ; Woolston, A; Semiannikova, M; Spain, G; Barber, LJ; Matthews, N; Rao, S; Watkins, D; Chau, I; Coukos, G; Racle, J; Gfeller, D; Starling, N; Cunningham, D; Bassani-Sternberg, M; Gerlinger, M (2019-11-18)
      BACKGROUND:Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomics ...
    • Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia 

      Tuset, E; Matutes, E; Brito-Babapulle, V; Morilla, R; Catovsky, D
      T-cell prolymphocytic leukaemia (T-PLL) is an aggressive disease often resistant to conventional chemotherapy. Long lasting remissions with the monoclonal antibody CAMPATH-1H (anti-CD52) have been documented. We describe ...